CARB-X funds take Locus Biosciences' running total close to $1 billion

10 November 2020

USA-based Locus Biosciences, a biotech developing CRISPR-enhanced precision antibacterial products, has announced a $12.5 billion partnership with Combatting Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) that takes its total investment pledges since the start of 2019 close to $1 billion.

The contract with the non-profit organization follows the deal with Johnson & Johnson (NYSE: JNJ) worth up to $818 million, as well as the recent $144 million partnership with the Biomedical Advanced Research and Development Authority (BARDA), a government agency established to help secure the USA from influenza, pandemics and emerging infectious diseases.

Locus’ agreement with CARB-X involves the development of LBP-KP01, a CRISPR Cas3-enhanced bacteriophage product targeting the bacterial pathogen Klebsiella pneumoniae (K. pneumoniae) causing recurrent urinary tract infections. The company also intends to develop the product for infections of other body sites, such as lung infections, intra-abdominal infections, and bacteremia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK